AHA 2008: Blood test identifies heart failure patients in ER
This article was originally published in Clinica
Executive Summary
A new blood test identifies the sickest heart failure patients better than current tests used in US emergency departments, a trial has shown. Presented at the AHA meeting, the BACH study followed 1,641 patients who experienced difficulty breathing upon arrival at the emergency department. The researchers found that the MR-proADM test, developed by German firm Brahms, was prognostically accurate 73.1% of the time, making it superior to the commonly-used B-natriuretic peptide (BNP) test (60.6%) and the NTproBNP test (63%). The new test also predicted the 90-day mortality of these patients. The MR-proADM test indirectly measures adrenomedullin, which affects blood vessel dilation and is implicated in many cardiac and infectious diseases. It was CE marked for sale in Europe in October; US approval applications will be submitted in early 2009.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.